Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of $0.07, $0.20 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $19.99 million versus the consensus estimate of $19.27 million.

2025 Financial Guidance

Operating Expenses ( excluding share-based compensation) : The Company continues to expect full year 2025 R&D expenses of $32 million to $38 million and SG&A expenses of $50 million to $60 million, in each case excluding share-based compensation.
Share-Based Compensation: The Company continues to expect full-year share-based compensation expenses of $18 million to $20 million.
Non-GAAP Net Income from Operations7: Achieved breakeven non-GAAP net income in Q3 2025; non-GAAP margin expected to remain at similar breakeven levels in Q4 2025, excluding one-time items, reflecting sustained operating discipline.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.